Professor Malcolm Ranson
Senior Lecturer and Honorary Consultant in Oncology
School of Cancer and Imaging Sciences
Faculty of Medical & Human Sciences
University of Manchester
c/o Department of Medical Oncology
Christie Hospital NHS Trust
Wilmslow Road
Manchester
M20 4BX
Selected publications
2007
- Ranson, MR, Hersey, P, Thompson, D, Beith, J, McArthur, G, Haydon, A, Davis, I, Kefford, R, Mortimer, P, Harris, P, Baka, S, Seebaran, A, Sabharwal, A, Watson, A, Margison, GP, Middleton, M. (2007). Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. J Clin Oncol, 25( 18), 2540-5. further details
2002
- Baselga, J, Rischin, D, Ranson, MR, Calvert, H, Raymond, E, Kieback, D, Kaye, S, Gianni, L, Harris, A, Bjork, T, Averbuch, S, Feyereislova, A, Swaisland, H, Rojo, F, Albanell, J. (2002). Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol, 20( 21), 4292-302. Full text doi:10.1200/JCO.2002.03.100 further details
- Ranson, MR, Hammond, L, Ferry, D, Kris, M, Tullo, A, Murray, P, Miller, V, Averbuch, S, Ochs, J, Morris, C, Feyereislova, A, Swaisland, H, Rowinsky, E. (2002). ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol, 20( 9), 2240-50. further details
2001
- von Pawel, J, Gatzemeier, U, Pujol, J, Moreau, L, Bildat, S, Ranson, MR, Richardson, G, Steppert, C, Rivière, A, Camlett, I, Lane, S, Ross, G. (2001). Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol, 19( 6), 1743-9. further details